title: The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression.
abstract: BACKGROUND
  The intensity (loudness)-dependent amplitude change (IDAP) of auditory evoked event-related potential (ERP) components has been suggested as an indicator of central serotonergic neurotransmission. In patients with major depression, associations of high IDAP with favorable SSRI treatment outcome have been reported. This is the first study to assess the predictive value of the IDAP in SNRI treatment.
  
  
  METHODS
  We evaluated the pre-treatment intensity-dependent change of auditory evoked P1, N1, P2, and P1/N1 and N1/P2 peak-to-peak amplitudes in 14 inpatients with major depressive episode (DSM IV) in the course of 24 days of treatment with the SNRI reboxetine (6-12 mg/d).
  
  
  RESULTS
  Our data revealed a highly significant correlation between lower intensity-dependent N1 amplitude slopes prior to reboxetine treatment and stronger decrease of HDRS total score at Fz ( r = 0.86, P < 0.001), Fcz ( r = 0.91, P < 0.001), and Cz ( r = 0.93, P < 0.001).
  
  
  CONCLUSIONS
  This result corroborates the hypothesis of the IDAP as a differential indicator of serotonergic versus noradrenergic antidepressant psychopharmacotherapy.
authors.affiliation: Clinic for Psychiatry and Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, Essen, Germany. thomas.linka@uni-essen.de
authors.forename: T
authors.initials: T
authors.lastname: Linka
authors.forename: B W
authors.initials: BW
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Bender
authors.forename: G
authors.initials: G
authors.lastname: Sartory
authors.forename: M
authors.initials: M
authors.lastname: Gastpar
mesh_terms: D000161:Acoustic Stimulation / Q000379:methods; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004307:Dose-Response Relationship, Radiation; D004566:Electrodes; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D000077593:Reboxetine; D013223:Statistics as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine